Ian W. Flinn, MD, PhD, on CLL/SLL: Effect of Dose Modifications on Response to Duvelisib

Posted: Thursday, August 1, 2019

Ian W. Flinn, MD, PhD, of the Sarah Cannon Research Institute, discusses findings from the DUO trial on dose interruptions and reductions of duvelisib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and their effect on side effects and progression-free survival.